Related Experiment Video
Updated: May 20, 2025
Methodology for Sputum Induction and Laboratory Processing
Published on: December 17, 2017
Mepolizumab: Which condition benefits more: Nasal polyps or eosinophilic asthma?
Elif Açar1, Serpil Köylüce1, Serhat Şeker1
1Division of Allergy and Clinical Immunology, Department of Chest Diseases, Erciyes University Faculty of Medicine, Kayseri, Türkiye.
Introduction:
The negative effects of eosinophilic severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) on quality of life are well known. The present study aimed to evaluate the impact of mepolizumab treatment on the quality of life of patients diagnosed with eosinophilic severe asthma and CRSwNP.
Materials And Methods:
Patients with CRSwNP and eosinophilic severe asthma who had been receiving mepolizumab 100 mg/month for at least six months as treatment were eligible for the study. Patients were assessed using quality of life and disease control questionnaires for both diseases before and during the sixth month of treatment.
Result:
Forty-nine patients were included in the present study. Compared to the pre-treatment period, there was significant clinical improvement in quality of life for both rhinitis and asthma following mepolizumab treatment. The changes before and after the treatment were found as follows: Rhinitis Quality of Life Scale [44 (23-72); 25 (6-57); p< 0.001], Nasal Congestion Symptom Assessment Scale [13.0 (8-20); 9.0 (0-20); p< 0.001], Sino-Nasal Outcomes Test-22 (63.16 ± 17.9; 44.16 ± 21.33; p< 0.001), Asthma Quality of Life Questionnaire (111.06 ± 25.17; 142.67 ± 28.04; p< 0.001), Asthma Control Test [16 (6-21); 22 (14-25); p< 0.001]. Before mepolizumab treatment, 20 patients defined that CRSwNP and 29 patients defined that asthma affected their quality of life primarily. After six months of mepolizumab treatment, 38 patients defined that CRSwNP and 11 patients defined that asthma affected their quality of life primarily.
Conclusions:
Our results showed that mepolizumab is an effective treatment option for eosinophilic severe asthma and CRSwNP in patients having both diseases. Before mepolizumab, most patients' quality of life was affected by asthma symptoms, but this changed, and their quality of life began to be affected primarily by CRSwNP symptoms. This suggests that mepolizumab treatment is more effective in suppressing asthma symptoms than suppressing nasal polyp symptoms.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:24Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...